Latest Articles
-
Medtronic’s Two Year Study Reveals Positive Results For Its CoreValve System
Medtronic ‘s (NYSE: MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continued to report positive data at two years for high-risk patients. The study shows the efficacy of TAVR for high-risk patients over surgical aortic ...
-
Medical Devices Weekly Notes: Medtronic and Boston Scientific
Last week was eventful for Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) within the medical device sector. Medtronic is likely to expand its market presence in the Neuromodulation division as it acquired a privately held company, Advanced...
-
Heart Devices Drive Medtronic’s Robust Earnings
Medtronic (NYSE: MDT) reported better-than-expected fiscal third quarter results on Tuesday, February 17, with operational revenue growing 7.5% year-over-year (y-o-y) to about $4.32 billion, driven by balanced growth across business divisions and...
-
Medtronic Earnings Preview: Key Businesses In Focus
Medical device maker Medtronic (NYSE: MDT) is scheduled to release its third quarter fiscal 2015 results on Tuesday, February 17. In the previous quarter, the company reported operational revenue growth of 5% year-over-year (y-o-y) to about $4.4...
-
Medtronic-Covidien Deal May Close By Jan 29
There is a possibility that Medtronic’s acquisition of Covidien could close by the end of this month. Following a hearing before the Irish High Court on Monday, Covidien announced that its petition to be acquired by Medtronic is scheduled t...
-
Medtronic-Covidien Deal Receives Shareholder Approval
Medtronic ‘s (NYSE: MDT) shareholders approved its $43 billion Covidien acquisition on Tuesday, with shareholders representing 75% of its shares outstanding voting in its favor. With the deal also getting approved by Covidien’s shareh...
-
Medtronic’s Drug Coated Balloon Enters U.S. With FDA Approval
Medtronic ‘s (NYSE: MDT) new year has started on a positive note with its IN.PACT Admiral drug-coated balloon (DCB) getting approved by the U.S. Food and Drug Administration Monday. The FDA approval follows positive results of the company&#...
-
Medtronic Reports Positive Study Results For Angioplasty Device
Global medical device major Medtronic (NYSE: MDT) recently reported results of a study which stated that its IN.PACT Admiral drug-coated balloon (DCB) performed better than standard balloon angioplasty in the treatment of periphery artery disease...
-
Medtronic-Covidien Deal In Final Stages With Antitrust Approvals In Place
Medtronic (NYSE: MDT) is set to complete the acquisition of Covidien by early next year as it has received all the required antitrust clearances from about a dozen countries. In the last month, the deal has been approved by the U.S. Federal Trade...
-
Medtronic Earnings: Sales Surge On New Products And Emerging Markets
Medtronic (NYSE: MDT) reported strong fiscal second quarter results on Tuesday, with operational revenue growing 5% year-over-year (y-o-y) to about $4.4 billion, driven by balanced growth across business divisions and geographies. The companyR...
-
Medtronic Earnings Preview: U.S. ICD Sales, Emerging Markets In Focus
Medical device maker Medtronic (NYSE: MDT) is scheduled to release its second quarter fiscal 2015 results on Tuesday, November 18. In the previous quarter, the company reported operational revenue growth of 4% year-over-year (y-o-y) to about $4....
-
Medtronic To Go Ahead With Covidien Deal Despite Reduced Tax Benefits
Medtronic (NYSE: MDT) announced last week that it will go ahead with its Covidien buyout despite a recent notification by the U.S. Department of the Treasury and the Internal Revenue Service (IRS) discouraging tax-avoiding corporate inversion dea...
-
Weekly Medical Technology Update: Medtronic And Boston Scientific
It was an eventful week for medical technology and healthcare majors Medtronic, Inc. (NYSE: MDT) and Boston Scientific (NYSE:BSX). Medtronic ‘s stock touched a new record high on account of positive results of its IN.PACT SFA trial as well...
-
Study Shows Medtronic’s CoreValve TAVR Device Has Consistent And Cost Effective Performance
Medtronic, Inc. ‘s (NYSE: MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ongoing Transcatheter Cardiovascular...
-
Medtronic Reports Strong Sales On New Products And Robust U.S. Performance
Medtronic (NYSE: MDT) recently reported its fiscal first quarter results, with operational revenue growth of 4% year-over-year (y-o-y) to about $4.27 billion, driven by growing acceptance of new products and robust sales in the U.S. as well as em...
